- Executive Chairman to Continue to Fulfill Interim CEO Duties as Board Commences Executive Search - Data Correction for Fifth Patient in Phase 2 PNH Trial for …

[Read more...] about Akari Therapeutics Announces Resignation of CEO

NEW YORK and LONDON, April 27, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a …

[Read more...] about Akari Therapeutics Announces Edison’s Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II”

NEW YORK and LONDON, April 24, 2017 -Interim Phase 2 PNH data demonstrate positive response with Coversin™ -Phase 3 PNH program expected to commence in …

[Read more...] about Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and In Additional Clinical Targets